Drugs-for-viral-infections-anti-viral
Dengue is the most common
mosquito-borne, viral disease in the world. Dengue virus is a single stranded
positive polarity RNA virus, belongs to the family Flaviviridae. The Den-2 and Den-3 variants of
dengue are active this year and of the two, Den-2 is more prominent, according
to the Institute of Epidemiology, Disease Control and Researc...
Hand-foot-and-mouth disease (HFMD)
is a common but highly contagious acute viral infection due to an enterovirus infection. The disease is most common under the age of 10, and most are under 5
years of age (95%). It can uncommonly affect adults and tends to be more severe
in the elderly, immunocompromised, and pregnant women. What is the cause...
Dengue
is endemic in Bangladesh with recurrent outbreaks. Health officials in
Bangladesh have reported elevated dengue fever activity in Bangladesh during
2022. Dhaka and Chattogram has become a hotspot for dengue fever (DF).Why DF rising in August &
September?•
The risk of
dengue fever transmission in Bangladesh exists nationwide and...
Stepwise Approach of
Dengue Case ManagementPatients Group A: These are patients who are dengue
patients without warning sign and they may be sent home. These patients are
able to tolerate adequate volumes of oral fluids, pass urine at least once
every six hours. Patients Group B: These include patients with warning
signs. These are patients wh...
Russian health officials have approved a single-dose version
of the Sputnik V vaccine. Sputnik Light has showed nearly 80 per cent efficacy
in tests.
The single dose Sputnik Light vaccine demonstrated 79.4%
efficacy according to analyzed data taken from 28 days after the injection was
administered as part of Russia’s mass vaccination program...
In India, COVID-19 patients are developing a rare but fatal
fungal infection, called "black fungus."
Two cases of black fungus have been detected at BIRDEM
Hospital in patients who have recovered from Covid-19.According to an advisory issued by the Indian Council of
Medical Research the following conditions in Covid-19 patients increase the...
Baricitinib plus remdesivir was superior to remdesivir alone in reducing
recovery time and accelerating improvement in clinical status among
patients with Covid-19, notably among those receiving high-flow oxygen
or noninvasive ventilation. The combination was associated with fewer
serious adverse events.
The U.S. Food and Drug
Administration issued an emergency use authorization (EUA) for the drug
baricitinib, in combination with remdesivir, for the treatment of suspected or
laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two
years of age or older requiring supplemental oxygen, invasive mechanical...
Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens
appeared to have little or no effect on hospitalized COVID-19, as
indicated by overall mortality, initiation of ventilation and duration
of hospital stay. The mortality findings contain most of the randomized
evidence on Remdesivir and Interferon, and are consistent with
me...
In a paper on the interim findings on the four drugs, WHO's Solidarity
trial researchers in 30 countries return a clear negative.
The multi-country Solidarity trial
anchored by the World Health Organization (WHO) has concluded that none of the
four repurposed drugs that it examined — remdesivir, hydroxychloroquine (HCQ),...